Cidara Therapeutics AAQS 2024

Kaj počne Cidara Therapeutics?

Cidara Therapeutics Inc. is a biopharmaceutical company specializing in the development and marketing of innovative therapies for serious infectious diseases. The company was founded in 2013 and is headquartered in San Diego, California. The founders of Cidara Therapeutics Inc. aimed to develop a new class of antifungal drugs that are particularly effective against fungal infections. The underlying technology is based on the Cloudbreak® peptide platform, which allows for the production of drugs with improved efficacy and safety. The company also has research collaborations with leading scientists in the field of infectious diseases to advance the development of antibody therapy, vaccines, and other drugs. The business model of Cidara Therapeutics Inc. focuses on the development and marketing of innovative therapeutic products for unmet medical needs. The company has divided its products into three divisions: infectious diseases, oncology, and immunology. Cidara's product pipeline includes several innovative drugs that have shown efficacy in phase I and phase II clinical trials. The infectious diseases division initially focuses on the development of antifungal drugs for the treatment of Candida infections, which can be life-threatening for people with weakened immune systems. Cidara Therapeutics Inc. has already successfully completed a clinical trial for its lead product, rezafungin. Rezafungin is a long-acting, liposomal antifungal drug that enables a single dose for effective treatment of Candida infections. The oncology division focuses on the development of innovative immunotherapies that use the body's immune system to attack cancer cells. Cidara Therapeutics Inc. utilizes the Cloudbreak® platform technology to develop new drugs that specifically target certain types of cancer. The lead product in this pipeline is CD371, a monoclonal antibody targeting acute myeloid leukemia (AML). The immunology division focuses on developing therapeutics for autoimmune diseases that bring the body's immune system under medical control to reduce inflammation and damage to target organs. The lead product in this product line is Cloudbreak® immunomodulators, which specifically regulate immune responses and combat inflammation. Overall, Cidara Therapeutics Inc. is a promising company that focuses on the development and marketing of innovative drugs for high unmet medical needs. The company's diverse and well-balanced product pipelines in the areas of infectious diseases, oncology, and immunology demonstrate the great potential of this business model. With the advanced Cloudbreak® technology and the dedicated team, Cidara Therapeutics Inc. has the potential to take a global leadership role in drug development and save lives. Cidara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.